Dr Lal PathLabs: ₹168 Cr Genomics Acquisition

will acquire a 70% stake in SN Genelab for up to ₹168 crore. The company has approved the acquisition of a 70% stake in Gujarat-based SN Genelab Private Limited from its existing shareholders for approximately ₹168 crore. The transaction also includes a performance-linked earn-out of up to ₹31.5 crore. SN Genelab is expected to become a subsidiary of Dr Lal PathLabs after completion, which is targeted by November 30, 2026. SN Genelab operates in diagnostic genomics and reported FY26 turnover of ₹57.96 crore, compared with ₹53.36 crore in FY25. The acquisition therefore adds an existing genomics business rather than being a greenfield expansion. My view is that the acquisition gives Dr Lal PathLabs a way to expand its advanced diagnostics offering while gaining access to an established genomics operation. However, the purchase price needs to be evaluated against SN Genelab's revenue and future growth. The earn-out structure also means part of the consideration is linked to performance. I will watch integration, genomics revenue growth and the company's return on the acquisition investment. Stance: Tracking the acquisition for integration and earnings contribution. Disclosure: Add your actual holding, position or interest disclosure before publishing.